InvestorsHub Logo
icon url

cloudera

02/28/23 4:17 PM

#404571 RE: Examiner77 #404565

It would be the year of efficiency, meaning cost savings/cost cutting and there by the earnings would at least be 100% more from the last quarter to the next and so on. It would lead to increase in share price. I think by the end of the year AD will break even with his AMRN investment.
icon url

Whalatane

02/28/23 4:26 PM

#404573 RE: Examiner77 #404565

Ex. the only catalyst that matters in the short term imho are these results from MITIGATE

Other Outcome Measures:
Percentage of participants who die due to any cause [ Time Frame: 0-12 months ]
Percentage of participants experiencing a major adverse cardiovascular event [ Time Frame: 0-12 months ]
Death due to any cause, hospitalization for myocardial infarction, or hospitalization for ischemic stroke

Percentage of participants experiencing an expanded major adverse cardiovascular event [ Time Frame: 0-12 months ]
Major adverse cardiovascular events, hospitalization for acute coronary syndrome, and coronary revascularization (i.e., percutaneous coronary intervention and/or coronary artery bypass graft)



This is a high risk secondary prevention population .
ANY signs of risk reduction over this time frame will be a catalyst ...especially if the results are stat sig in a Total Event Analysis .

Poster laurent has looked at this trial in more detail so suggest U read his analysis .

As per Clinical Trials .gov ...data collection ends today .
Data is all in-house so Kaiser / AMRN will have a rough idea fairly fast if theres risk reduction .
I think around 1,000 patients in the active arm have been in this trial for about 1.5 yrs ...hopefully enough time for clear separation of event lines in at least this group.

If we don't have top line results on all Outcomes in this trial within the next 6 wks .....expect results to be buried in some poster at a conference in the future .

What would have me buying AMRN again ?.... CV Outcome results that confirmed to a significant degree the R-IT results . Denner needs that IMHO to convince Germany to reconsider reimbursement

Kiwi